Patients Call For Congressional Action on Drug Prices During COVID-19 Pandemic

WASHINGTON, DC — Patients For Affordable Drugs Now sent a letter to Capitol Hill this week urging Congress to focus on three topics in upcoming COVID-19 legislative packages: ensuring taxpayer investment into COVID-19 drugs is factored into prices, helping the nation prepare for future public health emergencies, and addressing the high list prices of prescription drugs as Americans struggle with the impact of the pandemic.
 
“COVID-19 did not make high drug prices go away — it worsened the crisis for patients,” the letter states. “Every dollar we pay in unjustified profits to drug corporations is a dollar we could use to support ordinary Americans whose health and economic well-being has been devastated by this pandemic. If we had unlimited resources as a nation, these choices wouldn’t matter. But we don’t.”
 
The letter, addressed to congressional leaders in the House and the Senate and signed by patients from all 50 states, calls for congressional action in three key areas:

1. Ensure taxpayers have a say in COVID-19 drug pricing. Since March, the Biomedical Advanced Research and Development Authority (BARDA) has awarded more than $1.2 billion to the pharmaceutical industry for COVID-19 drugs — with no stipulations on fair pricing. As partners in the scientific and funding processes, American taxpayers deserve a say in the price.
2. Prioritize long-term incentives for infectious disease research over short-sighted giveaways to the drug industry. Pharma does not need new incentives to develop COVID-19 drugs. The federal government is bankrolling research, sponsoring clinical trials, and eliminating all liability for drug corporations investing in COVID-19 drugs, and the pandemic’s global impact guarantees billions of buyers. Instead, Congress should invest in and incentivize research to prevent and prepare for future infectious disease outbreaks.
3. Lower drug prices now. The COVID-19 pandemic has only worsened the drug pricing crisis in the United States. Alongside soaring unemployment numbers, 27 million Americans could lose employer-based health insurance, exposing many of them to high list prices. Congress must take long-awaited action on drug prices immediately.

Patients For Affordable Drugs Now is an independent, bipartisan patient organization focused on policies to lower drug prices. P4ADNow does not accept funding from any organizations that profit from the development or distribution of prescription drugs.

Read the letter here.

###

WASHINGTON, DC — A new campaign by Patients For Affordable Drugs Now calls on Senators to support one of President Trump’s top priorities by passing legislation to lower prescription drug prices. The multi-million dollar campaign, launched today, urges Senators to stand with patients and the President in support of the Prescription Drug Pricing Reduction Act (S. 2543) — a bill that would stop drug company price gouging and lower costs for seniors.
 
“Americans of every political stripe agree that drug prices have got to come down,” said David Mitchell, a cancer patient and the founder of Patients For Affordable Drugs Now. “Patients are done with Big Pharma’s lies and outsized influence in Congress, and they’re ready to vote on the issue come November.”
 
The campaign is launching with two national TV ads featuring patients hurt by rising drug prices. Watch the videos, “Gail,” and “Jackie,” and read the transcripts below.
 
As part of the campaign set to run until late May, Patients For Affordable Drugs Now will also release radio and digital advertisements nationally and in key states that demonstrate the toll high prescription drug prices are taking on everyday Americans. In addition, the campaign will commission polling, fly patients to Washington, and offer patients a suite of tools to help them contact their elected officials and demand action to lower drug prices.
 
Starting today, P4ADNow will thank Sen. Joni Ernst (R-IA), the most recent Senator to endorse the Grassley-Wyden bill.

TV AD TRANSCRIPTS

“Jackie”
 
This is a four week supply of my chemotherapy —
It’s 20 pills, and it’s $20,000 every single month.
You know it’s hard enough thinking that I’m not going to live that long and to leave my husband alone.
But to leave him bankrupt? It’s devastating to me.
Millions of people like me are struggling — and drug prices just keep going up and up.
But now there are bipartisan proposals in Congress that would actually bring those prices down.
Mr. President, Congress, it’s time to make history.
The time is now.

“Gail”

My insulin used to cost $26 a vial.
Today, drug companies charge up to $350 a vial.
This is the same insulin formula I’ve been using for almost 30 years.
Regular middle class people like me — we need help.
Without Congressional intervention, many of us are struggling.
Many are dying.
Just because we can’t afford insulin.
Mr. President and Congress, we are counting on you. 

BACKGROUND

• Senate Finance Committee Chairman Chuck Grassley (R-IA) and Ranking Member Ron Wyden (D-OR) introduced the bipartisan Prescription Drug Pricing Reduction Act in July 2019.
• The bill would penalize drug companies for price hikes above inflation and cap out-of-pocket costs for seniors on Medicare at $3,100 per year.
• President Trump and bipartisan lawmakers support the bill, which passed the Senate Finance Committee in July.
• The bill could be included in a health extenders package with a deadline of May 22, 2020.

###

FORT WORTH, TX — Texas patients will join Senator John Cornyn at his roundtable today to share their stories about the high cost of their prescription drugs and to support the Senator in continuing to push for passage of his bipartisan Affordable Prescriptions for Patients Act. The legislation was introduced by Senator Cornyn and Senator Richard Blumenthal (D-CT) and aims to curb tactics drug companies use to game the patent system and block generic competition.

Below view the event details, hear from patients who will attend, and read more about the bill.

DETAILS

When: 1:20 PM, Tuesday, February 18, 2020
Where: Northside Community Health Center, Second Floor
              2332 Beverly Hills Drive
             Fort Worth, TX 76114

PATIENT PERSPECTIVE

Emily Grant, Dallas, cystic fibrosis: “I once had to pay $1,000 up front for a necessary inhaled antibiotic, Colistin. $1,000 is an outrageous cost, and I know that if something happens to my coverage, I could suddenly be faced with this cost again.”
 
Savanna Braun, The Woodlands, asthma, psoriatic arthritis, and other chronic conditions: “I will have to make major life decisions because of the cost of my drugs. These decisions range from which jobs I seek to whether or not I can afford certain medications or new therapies.”

Randall and Emma Barker, Wichita Falls, father and daughter with type 1 diabetes: “Both my daughter, Emma, and I live with type 1 diabetes. We have had to make real sacrifices to be able to afford the insulin we need to live.”

BACKGROUND

• The Affordable Prescriptions for Patients Act would:
  • Allow the Federal Trade Commission (FTC) to bring lawsuits against companies that engage in patent abuses.
  • Permit the FTC to investigate whether patent thickets on drugs were created with the intent of delaying generic competition.
  • Create an easier and more efficient court-case process for generic drugs seeking to enter the market.
• TYPES OF PATENT ABUSE:
  • Product hopping is when a brand drug company makes minor changes to its drug to earn a new patent and gain a new period of exclusivity. Product hops are most common when a brand drug is about to face competition from a generic competitor. The brand company will often transfer patients onto the new version of the drug for which they can charge unchallenged prices.
  • Brand drug companies also take advantage of the patent system by adding many trivial patents to their drugs, creating a “patent thicket” and allowing it to maintain longer periods of exclusivity and monopoly power.
  • Brand companies also force generic drug companies into a “patent dance” in which the brand company claims a generic company has infringed on its patents — which can add up to over 100 in some cases — forcing lengthy litigation periods that keep generic competition from coming to market.
• PATIENT IMPACT:
  • One of the drugs Savanna Braun takes, Eliquis, has had generic competition blocked for 34 years.
  • Between 2005 and 2015, more than 75% of drugs to receive new patents were existing drugs already on the market. Of the roughly 100 best-selling drugs, nearly 80% of drugmakers obtained an additional patent to extend products’ monopoly periods, meaning patients are facing crushing drug prices, longer.
  • Humira is the world’s top-selling drug; its drug maker, AbbVie, has blocked generic competition for 39 years while increasing the blockbuster’s price by 144% between 2012 and 2018. Patients who need the anti-inflammatory drug can no longer afford it and their chronic conditions go untreated or worsen.

###

WASHINGTON, DC — Patients For Affordable Drugs Now launched a new advertising campaign today thanking Senator Martha McSally for supporting the Prescription Drug Pricing Reduction Act, a bill that would stop drug company price gouging and lower costs for seniors. Drug pricing is top-of-mind for 2020 voters — nearly nine in 10 want Congress to prioritize lowering the prices of medications, polling shows.

Today’s campaign encourages Arizona patients to reach out to McSally’s office directly and thank her for standing with constituents — not Big Pharma.

“Senator McSally listened to her constituents who are calling out for relief from Big Pharma’s unrestrained price hikes,” said Ben Wakana, Executive Director of Patients For Affordable Drugs Now. “We want her to know how much patients appreciate her support and work to advance bipartisan reform that would help fix our broken system.”

Relief from high drug prices can’t arrive soon enough for patients like Luz Lopez who travelled from Arizona to Washington, DC to share her story with Senator McSally and advocate for reforms that would lower drug prices.
 
“I don’t know from one year to the next if I’ll be able to afford the prescriptions I need to treat multiple chronic conditions, including depression and anxiety,” Lopez said. “It is so meaningful to me that Senator McSally listened and stood up for me. I hope more members of Congress follow her lead.”

BACKGROUND

• Senate Finance Committee Chairman Chuck Grassley (R-IA) and Ranking Member Ron Wyden (D-OR) introduced the bipartisan Prescription Drug Pricing Reduction Act in July 2019.
• The bill would penalize drug companies for price hikes above inflation and cap out-of-pocket costs for seniors on Medicare at $3,100 per year.
• With her endorsement, McSally joined President Trump and bipartisan lawmakers in supporting the bill, which passed the Senate Finance Committee in July.
• The bill currently awaits a vote from the full Senate.

###

WASHINGTON, DC — In response to the Trump Administration’s announcement of a proposed rule that would allow the importation of certain prescription drugs, David Mitchell, a cancer patient and the founder of Patients For Affordable Drugs Now, issued the following statement:

“We are glad the administration has cracked the door open to safe importation of drugs from Canada and other countries. But it’s not a solution that will lower drug prices for the overwhelming majority of Americans. 

“We hope the administration will work with Congress to pass a comprehensive drug pricing reform package and finalize its international pricing index model, actions that would begin to address the fact that Americans pay two to three times more than citizens in other nations for the same drugs.”

BACKGROUND

• According to Canada’s acting ambassador to the United States, Canada represents 2 percent of global pharmaceutical consumption compared with the United States’ 44 percent. This raises questions about Canada’s ability to meet the demands of supplying drugs to the U.S. market.
• The administration’s notice of proposed rulemaking outlines two pathways for importation. The first pathway will guide importation efforts by states like Florida and Maine that passed importation laws during 2019 legislative sessions. The second pathway allows manufacturers to import foreign-made drugs under new drug codes — essentially releasing them from contractual obligations with pharmacy benefit managers (PBMs). Since manufacturers perpetually blame PBM contracts for high list prices, this second pathway provides pharma with an opportunity to put their money where their mouth is.
• Patients will not be allowed to import expensive biologic drugs such as insulin and Humira under the first pathway.

  ###

WASHINGTON, DC — In response to House passage of H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, David Mitchell, a cancer patient and the founder of Patients For Affordable Drugs Now, issued the following statement:

“Patients scored a major victory in the fight for lower drug prices today. We applaud the House of Representatives for passing this landmark legislation that will expand Medicare benefits, support innovation, and save America billions of dollars from lower drug prices.

“The House has done its job. Now the Senate must act.”

BACKGROUND

H.R. 3 would:

• Let Medicare negotiate lower drug prices and extend lower prices to all Americans with public or private sector insurance.
• Save $456 billion from drug price negotiations and reinvest $358 billion back into Medicare to add new dental, hearing, and vision benefits for seniors on Medicare.
• Cap out-of-pocket spending at $2,000 for Medicare beneficiaries. Currently, seniors can pay more than $15,000 a year for a single prescription drug.
• Stop drug company price gouging by requiring corporations to pay a rebate if drug prices increase faster than the rate of inflation.
• Support innovation and new drug development by investing savings from Medicare negotiations into the world-class research being done at the NIH, and which can be targeted to unmet need and public health priorities.

  ###

WASHINGTON, DC — In response to the Congressional Budget Office’s (CBO) score on H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, David Mitchell, a cancer patient and the founder of Patients For Affordable Drugs Now, issued the following statement:

“H.R. 3 will help fix our broken system and ensure Americans with private and public insurance get the drugs they need at lower prices.

“CBO confirmed the bill will put $456 billion in savings from lower drug prices to work for taxpayers. America’s seniors will benefit from new dental, hearing, and vision coverage, investments in innovative new drugs, and lower out-of-pocket costs.

“H.R. 3’s investment into the world-class research at the National Institutes of Health will more than offset the prediction of about two new drugs lost per year. As a patient whose life is completely dependent on new drugs, I’m confident innovation is protected under this landmark legislation.

“It’s time to pass H.R. 3.”

 ###

WASHINGTON, DC — In less than 24 hours, more than 1,600 patients from every state signed a petition supporting H.R. 3, landmark legislation to let Medicare negotiate lower drug prices. Patients For Affordable Drugs Now launched the petition this week as the House announced a vote on The Lower Drug Costs Now Act. The petition comes on the heels of television, radio, and digital advertisements in recent months that illustrate the impact of high prescription drug prices on everyday Americans. In addition, patient advocates from across the country have flown to Washington to meet their members of Congress and thousands more have written letters in support of policies to lower drug prices.

“Americans are being being ripped off, and we know Medicare negotiation is a common sense solution to drive down drug prices,” said David Mitchell, a cancer patient and the founder of Patients For Affordable Drugs Now. “Everyone, everywhere is tired of paying two to three times what other developed nations pay for the exact same prescription drugs. It’s time for the leaders in Washington to put aside differences and give the American public a win to lower drug prices.”

H.R. 3 would:

• Let Medicare negotiate lower drug prices and extend lower prices to all Americans with public or private sector insurance.
• Cap out-of-pocket spending at $2,000 for Medicare beneficiaries. Currently, seniors can pay more than $15,000 a year for a single prescription drug.
• Stop drug company price gouging by requiring corporations to pay Medicare if drug prices increase faster than the rate of inflation.
• Add hearing, dental, and vision coverage for Medicare beneficiaries.
• Support innovation and new drug development by investing savings from Medicare negotiations into the world-class research being done at the NIH.

Currently, nearly 1 in 3 Americans report not taking their medicines as prescribed because of the cost. Lower drug prices will mean better adherence to drugs, which will improve health outcomes and extend life expectancy for millions of Americans. That’s likely why nine of 10 Americans from both political parties agree one of Congress’ top priorities should be to lower drug prices.

  ###